Unknown

Dataset Information

0

Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosis.


ABSTRACT:

Background

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease trajectory. The aim of this study was to assess the potential of neutrophil-to-lymphocyte ratio (NLR) to predict outcomes in IPF.

Methods

We adopted a two-stage discovery (n = 71) and validation (n = 134) design using patients from the UCL partners (UCLp) cohort. We then combined discovery and validation cohorts and included an additional 794 people with IPF, using real-life data from 5 other UK centers, to give a combined cohort of 999 patients. Data were collected from patients presenting over a 13-year period (2006-2019) with mean follow up of 3.7 years (censoring: 2018-2020).

Findings

In the discovery analysis, we showed that high values of NLR (>/ = 2.9 vs < 2.9) were associated with increased risk of mortality in IPF (HR 2.04, 95% CI 1.09-3.81, n = 71, p = 0.025). This was confirmed in the validation (HR 1.91, 95% CI 1.15-3.18, n = 134, p = 0.0114) and combined cohorts (HR 1.65, n = 999, 95% CI 1.39-1.95; p < 0·0001). NLR correlated with GAP stage and GAP index (p < 0.0001). Stratifying patients by NLR category (low/high) showed significant differences in survival for GAP stage 2 (p < 0.0001), however not for GAP stage 1 or 3. In a multivariate analysis, a high NLR was an independent predictor of mortality/progression after adjustment for individual GAP components and steroid/anti-fibrotic use (p < 0·03). Furthermore, incorporation of baseline NLR in a modified GAP-stage/index, GAP-index/stage-plus, refined prognostic ability as measured by concordance (C)-index.

Interpretation

We have identified NLR as a widely available test that significantly correlates with lung function, can predict outcomes in IPF and refines cohort staging with GAP. NLR may allow timely prioritisation of at-risk patients, even in the absence of lung function.

Funding

Breathing Matters, GSK, CF Trust, BLF-Asthma, MRC, NIHR Alpha-1 Foundation.

SUBMITTER: Mikolasch TA 

PROVIDER: S-EPMC9722446 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosis.

Mikolasch Theresia A TA   George Peter M PM   Sahota Jagdeep J   Nancarrow Thomas T   Barratt Shaney L SL   Woodhead Felix A FA   Kouranos Vasilis V   Cope Victoria S A VSA   Creamer Andrew W AW   Fidan Silan S   Ganeshan Balaji B   Hoy Luke L   Mackintosh John A JA   Shortman Robert R   Duckworth Anna A   Fallon Janet J   Garthwaite Helen H   Heightman Melissa M   Adamali Huzaifa I HI   Lines Sarah S   Win Thida T   Wollerton Rebecca R   Renzoni Elisabetta A EA   Steward Matthew M   Wells Athol U AU   Gibbons Michael M   Groves Ashley M AM   Gooptu Bibek B   Scotton Chris J CJ   Porter Joanna C JC  

EClinicalMedicine 20221201


<h4>Background</h4>Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease trajectory. The aim of this study was to assess the potential of neutrophil-to-lymphocyte ratio (NLR) to predict outcomes in IPF.<h4>Methods</h4>We adopted a two-stage discovery (n = 71) and validation (n = 134) design using patients from the UCL partners (UCLp) cohort. We then combined discovery and validation cohorts and included an additional 794 people with IPF, using real-life dat  ...[more]

Similar Datasets

| S-EPMC6048712 | biostudies-literature
| S-EPMC9039554 | biostudies-literature
| S-EPMC11219835 | biostudies-literature
| S-EPMC5288996 | biostudies-literature
| S-EPMC8443385 | biostudies-literature
| S-EPMC10664513 | biostudies-literature
| S-EPMC8232097 | biostudies-literature
| S-EPMC9857771 | biostudies-literature
| S-EPMC8120068 | biostudies-literature
| S-EPMC6551461 | biostudies-literature